Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07698314

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cancer Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year–89 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

AHN Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States

Location contact

Clinical Trials Contact

CONTACT

[email protected]

412-330-6151

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20-89 years
  • Women prescribed exercise as a SOC
  • Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
  • Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
  • Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center

Exclusion criteria

  • Any current treatment with cytotoxic chemotherapy for breast cancer
  • Inability to safely engage in group sessions of resistance training as deemed by study PI
  • Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
  • Pregnant women
  • Males

Treatment and study plan

Conditioning Resistance Training

Behavioral

Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training".

Strength Resistance Training

Behavioral

Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8".

Hypertrophy Resistance Training

Behavioral

Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm".

Primary outcomes

  1. Change in Myokine Production After First Exercise Session

    Time frame: Immediately before and immediately after the first exercise session.

    Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined.

  2. Change in Myokine Production After Final Exercise Session of Each Week

    Time frame: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.

    Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined.

  3. Change in Myokine Production After Final Exercise Session of the Month (End of Study)

    Time frame: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).

    Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined.

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Contact

CONTACT

[email protected]

412-330-6151

Sponsors and collaborators

Lead sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Other

Registry information

Official study title

Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

Acronym: Myo-EXERTBC

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jul 13, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.